Ubiquitin‑specific peptidase 22 promotes proliferation and metastasis in human colon cancer

Yuan,Xiao; Wang,Hao; Xu,Aman; Zhu,Xingyang; Zhan,Yanqing; Wang,Wenbin

doi:10.3892/ol.2019.10872

Ubiquitin‑specific peptidase 22 promotes proliferation and metastasis in human colon cancer

Authors:
- Xiao Yuan
- Hao Wang
- Aman Xu
- Xingyang Zhu
- Yanqing Zhan
- Wenbin Wang
View Affiliations

Affiliations: Department of General Surgery, The Fourth Affiliated Hospital of Anhui Medical University, Anhui, Hefei 230022, P.R. China, Department of Pathology, Anhui Medical University, Anhui, Hefei 230032, P.R. China
Published online on: September 16, 2019 https://doi.org/10.3892/ol.2019.10872
Pages: 5567-5576
Copyright: © Yuan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colon cancer is one of the most common malignant tumors in the world; however, the mechanism underlying the progression of colon cancer remains unclear. In the present study, the expression of ubiquitin‑specific peptidase 22 (USP22) in paraffin sections of human colon cancer tissues and normal colon tissues were examined using immunohistochemistry. The human colon cancer cell lines HCT116 and HT29 were used for USP22 knockdown experiments, and functional assays were performed. The results demonstrated that compared with normal colon tissues, human colon cancer tissues exhibited upregulated expression of USP22 and this was associated with tumor lymph node metastasis and tumor stage in colon cancer tissues. In addition, upregulated expression of USP22 was significantly correlated with both lower relapse‑free survival and lower overall survival rates in patients with colon cancer. When USP22 was silenced in colon cancer cell lines, this resulted in a decrease in cell proliferation and metastatic behaviors. Furthermore, Bmi‑1 and Cyclin D2 were found to be positively regulated by USP22, which may have mediated the tumorigenic effects of USP22 in human colon cancer. The results of the present study may have significant implications for examining the underlying mechanisms of cancer development and the potential development of cancer therapeutics.

View Figures

View References

1	Meng X and Fu R: miR-206 regulates 5-FU resistance by targeting Bcl-2 in colon cancer cells. Onco Targets Ther. 11:1757–1765. 2018. View Article : Google Scholar : PubMed/NCBI
2	Evert J, Pathak S, Sun XF and Zhang H: A study on effect of oxaliplatin in MicroRNA expression in human colon cancer. J Cancer. 9:2046–2053. 2018. View Article : Google Scholar : PubMed/NCBI
3	Li Y, Gong P, Hou JX, Huang W, Ma XP, Wang YL, Li J, Cui XB and Li N: miR-34a regulates multidrug resistance via positively modulating OAZ2 signaling in colon cancer cells. J Immunol Res. 2018:74985142018. View Article : Google Scholar : PubMed/NCBI
4	Dou H, Shen R, Tao J, Huang L, Shi H, Chen H, Wang Y and Wang T: Curcumin Suppresses the Colon Cancer Proliferation by Inhibiting Wnt/β-catenin pathways via miR-130a. Front Pharmacol. 8:8772017. View Article : Google Scholar : PubMed/NCBI
5	Li L and Ma BB: Colorectal cancer in Chinese patients: Current and emerging treatment options. Onco Targets Ther. 7:1817–1828. 2014.PubMed/NCBI
6	Mishra J, Drummond J, Quazi SH, Karanki SS, Shaw JJ, Chen B and Kumar N: Prospective of colon cancer treatments and scope for combinatorial approach to enhanced cancer cell apoptosis. Crit Rev Oncol Hematol. 86:232–250. 2013. View Article : Google Scholar : PubMed/NCBI
7	Liu YR, Liang L, Zhao JM, Zhang Y, Zhang M, Zhong WL, Zhang Q, Wei JJ, Li M, Yuan J, et al: Twist1 confers multidrug resistance in colon cancer through upregulation of ATP-binding cassette transporters. Oncotarget. 8:52901–52912. 2017.PubMed/NCBI
8	He K, Chen D, Ruan H, Li X, Tong J, Xu X, Zhang L and Yu J: BRAFV600E-dependent Mcl-1 stabilization leads to everolimus resistance in colon cancer cells. Oncotarget. 7:47699–47710. 2016.PubMed/NCBI
9	Segditsas S and Tomlinson I: Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene. 25:7531–7537. 2006. View Article : Google Scholar : PubMed/NCBI
10	Hollis M, Nair K, Vyas A, Chaturvedi LS, Gambhir S and Vyas D: MicroRNAs potential utility in colon cancer: Early detection, prognosis, and chemosensitivity. World J Gastroenterol. 21:8284–8292. 2015. View Article : Google Scholar : PubMed/NCBI
11	Yu YJ, Nangia-Makker P, Farhana L and Majumdar APN: A novel mechanism of lncRNA and miRNA interaction: CCAT2 regulates miR-145 expression by suppressing its maturation process in colon cancer cells. Mol Cancer. 16:1552017. View Article : Google Scholar : PubMed/NCBI
12	Gong Z, Liu J, Xie X, Xu X, Wu P, Li H, Wang Y, Li W and Xiong J: Identification of potential target genes of USP22 via ChIP-seq and RNA-seq analysis in HeLa cells. Genet Mol Biol. 41:488–495. 2018. View Article : Google Scholar : PubMed/NCBI
13	Wang A, Ning Z, Lu C, Gao W, Liang J, Yan Q, Tan G and Liu J: USP22 induces cisplatin resistance in lung adenocarcinoma by regulating γH2AX-Mediated DNA damage repair and Ku70/Bax-mediated apoptosis. Front Pharmacol. 8:2742017. View Article : Google Scholar : PubMed/NCBI
14	Lee HJ, Kim MS, Shin JM, Park TJ, Chung HM and Baek KH: The expression patterns of deubiquitinating enzymes, USP22 and Usp22. Gene Expr Patterns. 6:277–284. 2006. View Article : Google Scholar : PubMed/NCBI
15	Armour SM, Bennett EJ, Braun CR, Zhang XY, McMahon SB, Gygi SP, Harper JW and Sinclair DA: A high-confidence interaction map identifies SIRT1 as a mediator of acetylation of USP22 and the SAGA coactivator complex. Mol Cell Biol. 33:1487–1502. 2013. View Article : Google Scholar : PubMed/NCBI
16	Zhang XY, Varthi M, Sykes SM, Phillips C, Warzecha C, Zhu W, Wyce A, Thorne AW, Berger SL and McMahon SB: The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression. Mol Cell. 29:102–111. 2008. View Article : Google Scholar : PubMed/NCBI
17	Yang X, Zang H, Luo Y, Wu J, Fang Z, Zhu W and Li Y: High expression of USP22 predicts poor prognosis and advanced clinicopathological features in solid tumors: A meta-analysis. Onco Targets Ther. 11:3035–3046. 2018. View Article : Google Scholar : PubMed/NCBI
18	Hoeller D and Dikic I: Targeting the ubiquitin system in cancer therapy. Nature. 458:438–444. 2009. View Article : Google Scholar : PubMed/NCBI
19	Ma Y, Fu HL, Wang Z, Huang H, Ni J, Song J, Xia Y, Jin WL and Cui DX: USP22 maintains gastric cancer stem cell stemness and promotes gastric cancer progression by stabilizing BMI1 protein. Oncotarget. 8:33329–33342. 2017.PubMed/NCBI
20	Ling S, Li J, Shan Q, Dai H, Lu D, Wen X, Song P, Xie H, Zhou L, Liu J, et al: USP22 mediates the multidrug resistance of hepatocellular carcinoma via the SIRT1/AKT/MRP1 signaling pathway. Mol Oncol. 11:682–695. 2017. View Article : Google Scholar : PubMed/NCBI
21	Xu G, Cai J, Wang L, Jiang LY, Huang JB, Hu R and Ding F: MicroRNA-30e-5p suppresses non-small cell lung cancer tumorigenesis by regulating USP22-mediated Sirt1/JAK/STAT3 signaling. Exp Cell Res. 362:268–278. 2018. View Article : Google Scholar : PubMed/NCBI
22	Kim D, Hong A, Park HI, Shin WH, Yoo L, Jeon SJ and Chung KC: Deubiquitinating enzyme USP22 positively regulates c-Myc stability and tumorigenic activity in mammalian and breast cancer cells. J Cell Physiol. 232:3664–3676. 2017. View Article : Google Scholar : PubMed/NCBI
23	Bosman FT, Carneiro F, Hruban RH and Theise ND: WHO classification of tumours of the digestive system4th. 3. International Agency for Research on Cancer; Lyon: 2010
24	Wang B, Wu ZS and Wu Q: CMIP promotes proliferation and metastasis in human glioma. Biomed Res Int. 2017:53401602017.PubMed/NCBI
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
26	Li DW, Tang HM, Fan JW, Yan DW, Zhou CZ, Li SX, Wang XL and Peng ZH: Expression level of Bmi-1 oncoprotein is associated with progression and prognosis in colon cancer. J Cancer Res Clin Oncol. 136:997–1006. 2010. View Article : Google Scholar : PubMed/NCBI
27	Zhang Z, Bu X, Chen H, Wang Q and Sha W: Bmi-1 promotes the invasion and migration of colon cancer stem cells through the downregulation of E-cadherin. Int J Mol Med. 38:1199–1207. 2016. View Article : Google Scholar : PubMed/NCBI
28	Schlormann W, Naumann S, Renner C and Glei M: Influence of miRNA-106b and miRNA-135a on butyrate-regulated expression of p21 and Cyclin D2 in human colon adenoma cells. Genes Nutr. 10:502015. View Article : Google Scholar : PubMed/NCBI
29	Li ZH, Yu Y, Du C, Fu H, Wang J and Tian Y: RNA interference-mediated USP22 gene silencing promotes human brain glioma apoptosis and induces cell cycle arrest. Oncol Lett. 5:1290–1294. 2013. View Article : Google Scholar : PubMed/NCBI
30	Wang Z, Zhu L, Guo T, Wang Y and Yang J: Decreased H2B monoubiquitination and overexpression of ubiquitin-specific protease enzyme 22 in malignant colon carcinoma. Hum Pathol. 46:1006–1014. 2015. View Article : Google Scholar : PubMed/NCBI
31	Ao N and Liu Y, Bian X, Feng H and Liu Y: Ubiquitin-specific peptidase 22 inhibits colon cancer cell invasion by suppressing the signal transducer and activator of transcription 3/matrix metalloproteinase 9 pathway. Mol Med Rep. 12:2107–2113. 2015. View Article : Google Scholar : PubMed/NCBI
32	Tang B, Tang F, Li B, Yuan SG, Xu Q, Tomlinson S, Jin JF, Hu W and He SQ: High USP22 expression indicates poor prognosis in hepatocellular carcinoma. Oncotarget. 6:12654–12667. 2015. View Article : Google Scholar : PubMed/NCBI
33	Zhao H, Tang H, Huang Q, Qiu B, Liu X, Fan D, Gong L, Guo H, Chen C, Lei S, et al: MiR-101 targets USP22 to inhibit the tumorigenesis of papillary thyroid carcinoma. Am J Cancer Res. 6:2575–2586. 2016.PubMed/NCBI
34	Shao Y, Zhang D, Li X, Yang J, Chen L, Ning Z, Xu Y, Deng G, Tao M, Zhu Y and Jiang J: MicroRNA-203 increases cell radiosensitivity via directly targeting Bmi-1 in hepatocellular carcinoma. Mol Pharm. 15:3205–3215. 2018. View Article : Google Scholar : PubMed/NCBI
35	Kim JS, Choi DW, Kim CS, Yu SK, Kim HJ, Go DS, Lee SA, Moon SM, Kim SG, Chun HS, et al: MicroRNA-203 induces apoptosis by targeting Bmi-1 in YD-38 oral cancer cells. Anticancer Res. 38:3477–3485. 2018. View Article : Google Scholar : PubMed/NCBI
36	Yan Y, Wang Y, Zhao P, Ma W, Hu Z and Zhang K: BMI-1 promotes self-renewal of radio- and temozolomide (TMZ)-resistant breast cancer cells. Reprod Sci. 24:1620–1629. 2017. View Article : Google Scholar : PubMed/NCBI
37	Li N, Jiang K, Fang LP, Yao LL and Yu Z: Knockdown of long noncoding RNA CCAT1 inhibits cell growth, invasion and peritoneal metastasis via downregulation of Bmi-1 in gastric cancer. Neoplasma. 65:736–744. 2018. View Article : Google Scholar : PubMed/NCBI
38	Koh H, Park H, Chandimali N, Huynh DL, Zhang JJ, Ghosh M, Gera M, Kim N, Bak Y, Yoon DY, et al: MicroRNA-128 suppresses paclitaxel-resistant lung cancer by inhibiting MUC1-C and BMI-1 in cancer stem cells. Oncotarget. 8:110540–110551. 2017. View Article : Google Scholar : PubMed/NCBI
39	Wang Y, Xue J, Kuang H, Zhou X, Liao L and Yin F: microRNA-1297 inhibits the growth and metastasis of colorectal cancer by suppressing Cyclin D2 expression. DNA Cell Biol. 36:991–999. 2017. View Article : Google Scholar : PubMed/NCBI
40	Zhong H, Yang J, Zhang B, Wang X, Pei L, Zhang L, Lin Z, Wang Y and Wang C: LncRNA GACAT3 predicts poor prognosis and promotes cell proliferation in breast cancer through regulation of miR-497/CCND2. Cancer Biomark. 22:787–797. 2018. View Article : Google Scholar : PubMed/NCBI
41	Huang F, Zhao H, Du Z and Jiang H: MiR-615 inhibits prostate cancer cell proliferation and invasion by directly targeting Cyclin D2. Oncol Res. 27:293–299. 2019. View Article : Google Scholar : PubMed/NCBI
42	Zeng Q, Tao X, Huang F, Wu T, Wang J, Jiang X, Kuang Z and Cheng B: Overexpression of miR-155 promotes the proliferation and invasion of oral squamous carcinoma cells by regulating BCL6/Cyclin D2. Int J Mol Med. 37:1274–1280. 2016. View Article : Google Scholar : PubMed/NCBI
43	Li YL, Wang J, Zhang CY, Shen YQ, Wang HM, Ding L, Gu YC, Lou JT, Zhao XT, Ma ZL and Jin YX: MiR-146a-5p inhibits cell proliferation and cell cycle progression in NSCLC cell lines by targeting CCND1 and CCND2. Oncotarget. 7:59287–59298. 2016.PubMed/NCBI